Monoclonal Antibody Therapy Market Analysis
Monoclonal antibodies are laboratory-produced antibodies that are whose purpose is to serve as the substitute of natural antibodies that can enhance or repeat the immune system’s attack on harmful cells. Market Research Future (MRFR) has published and released a research report about the global monoclonal antibody therapy market that estimates boost for this Global Monoclonal Antibody Therapy Market size at 10.5% CAGR (Compound Average Growth Rate) between 2016 and 2022. In terms of market value, the worth of global monoclonal antibody therapy market has been estimated to be the US $ 140 bn by the end of the forecast period.
Analyzing the market structure, this report offers insights about factors affecting the market growth. Estimating the market size and forecasting the revenue, this reports covers and observes the competitive developments of market players that include mergers and acquisitions, joint ventures, new product developments, research and developments (R&D), and strategic alliances.
The major factors strengthening the growth of the global monoclonal antibody therapy market are rising health awareness, an unhealthy lifestyle lowering the immunity of consumers and increasing spending on healthcare.
The global monoclonal antibody therapy market has been segmented on the basis of application, end user, source, and lastly, region. The application-based segmentation segments this market into analytical & chemical uses, autoimmune diseases, cancer treatment, diagnostic test, hematological disorders, and others. Based on the end user, the market has been segmented into clinics, hospitals, research laboratories, and others. Regarding source, the market has been segmented into chimeric, human, humanized, recombinant, and other.
Depending on geographic region, monoclonal antibody therapy market is segmented into four key regions: America, Europe, Asia-Pacific, and Middle East & Africa. Globally, America is the largest market for monoclonal antibody therapy. North American region is the leading market in the America region. Europe is the second-largest market globally for monoclonal antibody therapy which is expected to continue its growth in the near future. Asia pacific region is expected to be fastest growing region in monoclonal antibody therapy market.
Europe is the second largest regional market, and it is expected to grow during the forecast period. The factors backing the growth of this market include a high density of population, established healthcare sector, high level of technological advancement that is second only to North America, and presence of many key market players. The main country-specific markets in this region are the strongest economies known as France, Germany, and the UK, followed by the remaining countries of Europe.
The Asia Pacific is another significant market as healthcare sector is developing in countries like China and India. Advanced medical facilities and rapid technological advancement are available in Japan. The rural market in countries like China and India is still untapped which due to the high density of population can be a lucrative market once tapped into. Many key market players are based in this region too. During the forecast period, the Asia Pacific region is likely to emerge as the fastest growing regional market.
The MEA region has the least market share due to poor countries, lack of awareness, lack of education, low standard of medical facilities, lack of healthcare facilities, and majority governments not considering healthcare a priority.
Obtain Premium Research Report Details @ https://www.marketresearchfuture.com/reports/monoclonal-antibody-therapy-market-2089
Monoclonal Antibody Therapy Market Key Players
The key players in the global monoclonal antibody therapy market include AbbVie Inc. (USA), Amgen Inc. (USA), Bayer AG (Germany), Biogen Inc. (USA), Bristol – Myers Squibb Company (USA), F. Hoffmann-La Roche Ltd. (Switzerland), GenScript (USA), GlaxoSmithKline PLC (UK), Johnson & Johnson (UK), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer Inc. (USA), Sanofi (France), and Sigma-Aldrich Co. LLC (USA).
Latest Industry News
Tychan has successfully conducted the Phase 1 trial of TY014, a first-in-class monoclonal antibody candidate treatment for Yellow Fever (YF). 13 DEC 2018
The meta-analysis of 10 randomized controlled trials has confirmed that human monoclonal antibody denosumab can more effectively increase the bone mass in patients with low bone mineral density or osteoporosis. This is something that any other bisphosphonate therapy cannot do. 13 DEC 2018